Fig. 2From: A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinibComputerized tomography (CT) scans showing a decrease in an implant close to the hepatic flexure of the colon after the patients have started taking selumetinib since June 2008Back to article page